The FDA, on May 22, approved Opvee, the first nalmefene hydrochloride nasal spray for the emergency treatment of known or suspected opioid overdose in adults and children 12 years of age and older. This product is available by prescription and is intended for use in healthcare and community settings. As part of the FDA’s Overdose Prevention Framework, the agency continues to take actionable steps to increase availability and expand access to overdose reversal products.
Additional information is available at FDA.gov.
